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Abstract: The endocannabinoid system and cannabinoid-based treatments have been involved 
in a wide number of diseases. In particular, several studies suggest that cannabinoids and endo-
cannabinoids may have a key role in the pathogenesis and therapy of multiple sclerosis (MS). In 
this study we highlight the main ﬁ  ndings reported in literature about the relevance of cannabinoid 
drugs in the management and treatment of MS. An increasing body of evidence suggests that 
cannabinoids have beneﬁ  cial effects on the symptoms of MS, including spasticity and pain. In 
this report we focus on the effects of cannabinoids in the relief of spasticity describing the main 
ﬁ  ndings in vivo, in the mouse experimental allergic encephalomyelitis model of MS. We report 
on the current treatments used to control MS symptoms and the most recent clinical studies 
based on cannabinoid treatments, although long-term studies are required to establish whether 
cannabinoids may have a role beyond symptom amelioration in MS.
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Introduction
Cannabis contains a series of compounds, but it has been found that the major psychoac-
tive ingredient is Δ9-tetrahydrocannabinol (THC) (Mechoulam and Gaoni 1967). Two 
selective cannabinoid receptor subtypes have been identiﬁ  ed so far (Matsuda et al 1990; 
Munro et al 1993), CB1 and CB2, that are expressed in nervous and peripheral cells. 
THC mediates the majority of its activities through stimulation of cannabinoid recep-
tors CB1, which are expressed throughout the central nervous system (CNS) (Matsuda 
et al 1990; Howlett et al 2002). Following the discovery of the receptors, fatty acid 
endogenous ligands, such as anandamide (AEA) and 2-arachidonoyl glycerol (2-AG), 
have been discovered in mammalian animal and human nervous tissues (Devane et al 
1992; Sugiura et al 1995), and a degradation system including a putative re-uptake 
mechanism and hydrolytic enzymes has been identiﬁ  ed (Devane et al 1992; Deutsch 
and Chin 1993; Mechoulam et al 1995; Dinh et al 2002; Saario and Laitinen 2007). 
A whole endogenous signaling system consisting of cannabinoid receptors, endocan-
nabinoids, and the proteins for their synthesis and inactivation led to the deﬁ  nition of 
the endocannabinoid system.
The endocannabinoid system functions to regulate synaptic neurotransmission 
(Kreitzer and Regehr 2001; Ludányi et al 2008) and tonically controls clinical signs 
such as spasticity and tremor that develop in mouse models of multiple sclerosis (MS) 
(Pryce and Baker 2007). This provides objective evidence to support the claims of MS 
patients that cannabis may have a beneﬁ  t in symptom management (Bifulco et al 2007), 
a claim further supported by some recent clinical trials of medical cannabis extracts 
(Killestein et al 2002; Robson et al 2002; Vaney et al 2002). There is in vitro evidence 
showing that cannabinoids can also regulate glutamate release, oxidant free radicals 
and calcium inﬂ  uxes (Kreitzer and Regehr 2001; Howlett et al 2002; Rea et al 2007; Neuropsychiatric Disease and Treatment 2008:4(5) 848
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Lauckner et al 2008; Sidlò et al 2008), which, in excess, can 
cause neuronal death in neuroinﬂ  ammatory disease (Kapoor 
et al 2003).
Recent studies have suggested that cannabinoid-based 
treatments may be beneﬁ  cial in a wide number of diseases. 
The pharmacological activity of AEA and 2-AG has been 
thoroughly examined and shown to be similar to that of some 
psychotropic plant cannabinoids, namely THC (Battista 
et al 2006). In particular, they have been found to exert a 
neuromodulatory effect (Navarrete and Araque 2008) on the 
synthesis, release and action of neurotransmitters. Some of 
these neurotransmitters, eg, dopamine, γ-aminobutyric acid, 
and glutamate, have been recently implicated in the genesis 
of experimental allergic encephalomyelitis (EAE) (Bolton 
and Paul 2006), an animal model of inﬂ  ammatory disease 
of the CNS myelin.
Cannabinoids and multiple sclerosis
MS is one of the most common chronic and disabling disor-
ders of the CNS caused by demyelination (loss of insulating 
sheath) of nerve ﬁ  bers. The disease usually begins in young 
adulthood and affects women more frequently than men 
(2:1). Common symptoms include fatigue, balance problems, 
muscle weakness, incontinence, muscle spasm, pain, and 
tremor. Clinical studies indicate that MS is characterized by 
at least two distinct phases, one that is dominated by acute 
relapses and one by steady progression. Both genetic and 
environmental factors seem to contribute synergistically to 
the manifestation and progression of the disease. MS usually 
starts with a relapsing – remitting course (RR-MS); over time, 
the number of relapses decreases, and most patients develop 
progressive neurological deﬁ  cits that occur independently 
of relapses (the so-called secondary progressive phase). In 
a few cases, MS begins with a primary progressive course 
(PPMS) without acute relapses. In general, the progression 
rate in RR-MS is comparable with that of PP-MS as soon as 
the patients enter the secondary progressive phase (Malﬁ  tano 
et al 2005). CNS lesions, frequently detected in RR-MS phase, 
are usually located in areas of white matter, and are often 
characterized by a disturbance of the blood – brain barrier, 
local oedema and demyelination, features that are compatible 
with an inﬂ  ammatory process, while in PP-MS, such inﬂ  am-
matory activity is much less conspicuous (Miller et al 1998). 
Global brain atrophy, however, is more dominant in the pro-
gressive stage and seems to correlate with disability (Losseff 
et al 1996; Fox et al 2000). These ﬁ  ndings indicate that early 
in the disease, ongoing inﬂ  ammatory activity is present in 
most patients and is responsible for the relapsing – remitting 
course, whereas a distinct process might be operative in the 
progressive phase of the disease, when inﬂ  ammatory activity 
diminishes despite faster evolution of disability. Histologi-
cal hallmarks of active MS include inﬁ  ltrations of T cells, 
macrophages, and B cells, degradation of myelin, and, to a 
lesser extent, axons, and reactive changes of astrocytes and 
microglia (Lassmann et al 2001). Autoimmunity is thought 
to drive the development of inﬂ  ammatory lesions that induce 
the primary demyelination, which results in the inhibition 
of normal neurotransmission (Compston and Coles 2002). 
Current treatment of MS is based on anti-inﬂ  ammatory, 
immunosuppressive, and immunomodulatory drugs, but usu-
ally the therapy is partially effective and with risks of side 
effects that patients are often unable to tolerate.
Recently, it has been reported that during CNS inﬂ  am-
mation, the endocannabinoid system is highly activated 
and the endocannabinoid an anandamide (AEA) protects 
neurons from inﬂ  ammatory damage by CB (1/2) receptor-
mediated rapid induction of mitogen-activated protein kinase 
phosphatase-1 (MKP-1) in microglial cell. The release of 
AEA in injured CNS tissue might represent a new mecha-
nism of neuro-immune communication during CNS injury, 
which limits immune response after primary CNS damage 
(Compston and Coles 2002). Furthermore, evidence suggests 
that endocannabinoids have immunosuppressant and anti-
inﬂ  ammatory properties, they downregulate the production 
of T helper 1 (Th1) cytokines, enhancing the production of 
T helper 2 (Th2) cytokines, since a polarization of T cell 
response towards a Th2 phenotype has been associated 
with therapeutic beneﬁ  t in MS, while a shift towards Th1 
has been associated with disease progression (Matsuda et al 
1990; Hemmer 2002). A recent study showed the modula-
tion of cytokines of the IL-12 family by cannabinoids in 
macrophages and brain microglia. Murine primary cultures of 
macrophage and microglia activated by lipopolysaccharide/
IFN-γ and Theiler’s virus were used to study the effects of 
cannabinoids on the regulation of IL-12 and IL-23 mRNA 
and protein IL-12 p40. It was observed that cannabinoids 
negatively regulate the production of these cytokines by 
microglial cells in part due to the activation of CB2 receptors. 
The effects of cannabinoids on cytokine brain work and on 
the regulation of neuroinﬂ  ammatory processes may affect 
chronic inﬂ  ammatory demyelinating diseases such as MS 
(Correa et al 2007).
Anecdotal reports have suggested that cannabinoids 
signiﬁ  cantly relieve the symptoms of MS, although a crucial 
point for their therapeutic application is the full assessment 
of their psychotropic effects. This has led some MS patients Neuropsychiatric Disease and Treatment 2008:4(5) 849
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to self-medicate with cannabis, which is suggested to be 
beneﬁ  cial in controlling symptoms such as spasticity, pain, 
tremor, and bladder dysfunction.
Several other plant cannabinoids, which have little or no 
psychoactive action, have been identiﬁ  ed; their biosynthetic 
relationships have been established, and the possible contri-
bution that they make to some of the proposed therapeutic 
actions of cannabis has been suggested. In particular, can-
nabidiol and the cannabinoic acids seem to be promising 
therapeutic tools, even though their sites of action are still 
not well understood (Pacher et al 2006).
Cannabinoids and spasticity
Many studies reporting the effects of cannabinoids in in vivo 
models of MS have been performed. We here summarize the 
main ﬁ  ndings described in literature about the antispastic 
properties of cannabinoids and their derived molecules. In 
mice with chronic relapsing experimental allergic encepha-
lomyelitis (CREAE), an animal model of MS, evidence has 
been presented that both exogenous and endogenous can-
nabinoids, via cannabinoid receptors, alleviate spasticity and 
tremors (Pryce and Baker 2007). Intravenous administration 
of THC and also R (+)-WIN55,212-2, a potent synthetic 
agonist of CB1 and CB2, rapidly decreased both the frequency 
and amplitude of tremors in limbs and hind limb spasticity 
of mice with this disease. Two lines of evidence suggest that 
these two beneﬁ  cial effects are mediated by cannabinoid 
receptors. Firstly, the S(-)- enantiomer of WIN55,212-2, 
and cannabidiol, which are both very weak agonists of CB1 
and CB2 receptors, did not reduce spasticity. Secondly, 
SR141716, which is a selective CB1 receptor antagonist, 
and SR144528, which is a selective CB2 receptor antago-
nist, prevented R(+)-WIN55,212-2 from inhibiting tremor. 
These ﬁ  ndings are very important because they may lead 
to novel strategies for the treatment of MS-induced tremor 
and spasticity, for which no efﬁ  cacious remedy has yet been 
developed. A crucial point that deserves further investiga-
tion, at least if therapeutic applications are to be developed is 
the full assessment of the possible psychotropic side effects 
of intravenous administration of cannabinoids. Methanan-
damide, a CB1-receptor-selective and metabolically stable 
analogue of the endocannabinoid anandamide (Mechoulam 
et al 1998), was almost as potent as R (+)-WIN55,212-2 
against hind limb spasticity in mice with CREAE. This ﬁ  nd-
ing implies that drugs based on endocannabinoids, which 
have been reported to have very low potential for physical 
dependence (Aceto et al 1998), could also be used in the treat-
ment of MS-induced spasticity. Another nonpsychoactive 
endogenous compound, the anti-inﬂ  ammatory mediator PEA 
(Lambert and Di Marzo 1999), also induced a signiﬁ  cant, 
albeit transient inhibition of spasticity (Pryce and Baker 
2007); however, the mechanism of action of this compound, 
which does not bind appreciably to CB1 or CB2 receptors, is 
still a matter of speculation (Lambert and Di Marzo 1999). 
SR141716 and with less potency SR144528, produced a 
signiﬁ  cant worsening of both tremors and spasticity of hind 
limbs and tail of CREAE mice (Pryce and Baker 2007). This 
ﬁ  nding raised the possibility that endocannabinoids such as 
anandamide and 2-AG (Mechoulam et al 1998), might be 
produced during CREAE in an attempt to compensate for 
the spastic defect. It was shown (Pryce and Baker 2007) 
that in normal ABH mice, whole brains and spinal cords 
contained similar levels of AEA, 2-AG and PEA. There 
was a modest increase of AEA in spastic brains compared 
with levels in normal brains. However, there was a marked 
increase of AEA, 2-AG and PEA within the spinal cord of 
spastic mice in comparison with normal animals. On the 
basis of these ﬁ  ndings, it was suggested that augmenting the 
levels of endogenous AEA might have a therapeutic effect, as 
exogenously applied and naturally occurring cannabimimetic 
metabolites, in particular AEA, can limit spasticity. Further-
more, the blockade of degradation with speciﬁ  c inhibitors 
may represent an alternative to increase the bioavailability 
of the endocannabinoids. Spasticity could be ameliorated by 
injection (10 mg/kg iv) of either the competitive reuptake 
inhibitor AM404 (Beltramo et al 1997) or the selective 
FAAH inhibitor, AM374 (Deutsch et al 1997), both of which 
have been shown to enhance AEA neuromodulatory actions 
(Beltramo et al 1997). These compounds have very low afﬁ  n-
ity for cannabinoid receptors (Beltramo et al 1997; Deutsch 
et al 1997). The antispastic effect of AM374 (1 mg/kg iv) 
was blocked by cannabinoid receptor antagonists (SR141716 
and SR144465, both 5 mg/kg iv) administered 20 min prior 
to AM374. These ﬁ  ndings suggest that the inhibitory effect 
on spasticity by AM374, which does not directly activate 
CB receptors (Deutsch et al 1997), is due to enhancement 
of endocannabinoid levels and subsequent stimulation of CB 
receptors. Both AEA and AM404 may also behave as vanil-
loid receptor (TRPV1) agonists (Zygmunt et al 1999; Smart 
and Jerman 2000; Smart et al 2000), but the role of TRPV1, 
if any, in control of spasticity is yet to be demonstrated. 
The extremely selective anandamide transporter inhibitor 
VDM11 (10 mg/kg iv), which has essentially no CB or 
TRPV1 agonist activity (De Petrocellis et al 2000), exerts 
a similar inhibition of spasticity. This ﬁ  nding, furthermore, 
supports the hypothesis that endocannabinoids mediate Neuropsychiatric Disease and Treatment 2008:4(5) 850
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control of spasticity via CB receptors. It was observed that 
agonists of  TRPV1 reduce bladder hyper-reactivity in MS 
(Fowler et al 1992) and have a modest antispastic effect 
in EAE mice, while a substantial effect was obtained with 
arvanil, a synthetic compound that can activate both CB1 
and TRPV1 receptors (Melck et al 1999). This effect persists 
using antagonists of CB1 and TRPV1 and in CB1 knockout 
EAE mice. According to these experimental ﬁ  ndings, it can 
be suggested that the antispastic effect of arvanil can be 
independent from CB1, CB2, or TRPV1 receptors and medi-
ated by a different site of action.
Treatment of spasticity in multiple 
sclerosis
MS is associated with disabling symptoms that often impair 
quality of life of patients affected by this neurological disease. 
These symptoms include muscle stiffness, spasms, pain, 
tremor, bladder dysfunction. Treatment of these symptoms, 
along with immunomodulation and immunosuppression, is 
therefore important in the overall management of this chronic 
disease and has achieved growing attention. Of the many 
symptoms encountered in MS, muscle spasticity (muscle 
stiffness as a result of increased pyramidal tone) and spasms 
occur in up to 90% of patients at some point (Ward 2008). 
This symptom often leads to considerable distress from pain, 
reduced mobility, and interference with activities of daily 
living in patients with MS; as muscle tone can be elevated 
persistently (tonic spasticity) or transiently as painful cramps 
(phasic spasticity). Spasticity develops also as a result of 
cerebral stroke or trauma, in children with cerebral palsy, 
in conditions and tumors of the spinal cord, and particularly 
following spinal injuries associated with spinal cord damage. 
The development and aggravation of spasticity is inﬂ  uenced 
by urinary tract infections, distension of the urinary bladder 
and rectum, pain, and pressure sores.
Antispastic treatment should primarily ameliorate motor 
function by reducing elevated muscle tone: patients may 
beneﬁ  t from being taught techniques for appropriate posture, 
positioning and weight transfer. Other goals of spasticity 
treatment are avoiding contractures and pressure ulcers, 
and facilitating patient self-care. Available treatments are 
often rather ineffective and no protocol for drug treatment 
of spasticity has been developed.
Physiotherapy for the relief of spasticity in MS 
(Giovannelli et al 2007; Pöllmann and Feneberg 2008), has 
not been extensively studied, despite being the standard 
approach, is insufﬁ  cient alone for most patients, thus anti-
spastic drugs are required. Among these antispastic drugs, 
the most commonly used are tizanidine and baclofen. A very 
recent report summarizes clinical trials demonstrating that 
the efﬁ  cacy of tizanidine is comparable with that of baclofen 
or diazepam with global tolerability data favoring tizanidine. 
A clinical case presentation demonstrated the effective use of 
tizanidine in combination with baclofen as a logical avenue 
for improved spasticity control. A large body of evidence 
supports the effective use of tizanidine monotherapy in the 
management of spasticity. A case study demonstrates that 
combination therapy can effectively control spasticity while 
better managing dose-dependent adverse events, although 
additional studies need to be performed to conﬁ  rm these 
results (Kamen et al 2008). Dantrolene and tolperisone are 
rarely prescribed. Benzodiazepines offer sufﬁ  cient antispastic 
effect, but are second-line drugs owing to their higher risk of 
side-effects such as sedation and dependence (Paisley et al 
2002; Shakespeare et al 2003). Gabapentin was shown to be 
effective in treating phasic spasticity (Mueller et al 1997; 
Cutter et al 2000).
Antispastic drugs are often of limited value in focal 
spasticity (eg, adductor spasticity or equinovarus deviation), 
but botulinum toxin type A reduces muscle tone effectively 
(Snow et al 1990; Hyman et al 2000). Numerous open-label 
trials as well as several masked and placebo-controlled 
studies in the last 10 years have demonstrated efﬁ  cacy of 
intramuscular injections of botulinum toxin for spasticity 
due to MS, brain and spinal cord injury, cerebral palsy, and 
stroke. Introduced several years ago, intrathecal baclofen 
administered via an infusion pump is an expensive method, 
at least two studies suggest that treatment reduces elevated 
muscle tone and frequency of spontaneous muscle spasms 
(Penn et al 1989; Middel et al 1997), although its efﬁ  cacy is 
reduced with long-term treatment.
Current treatments of MS are partially effective and with 
risks of side effects that patients are often unable to tolerate. 
This has led some MS patients to self-medicate with cannabis, 
which is suggested by anecdotal evidence to be beneﬁ  cial in 
controlling symptoms such as spasticity, pain, tremor, and 
bladder dysfunction, claims supported by recent clinical trials 
of medical cannabis extracts (Killestein et al 2002; Robson 
et al 2002; Vaney et al 2002).
Clinical studies
The first large scale study designed to assess the 
hypothesis of beneficial effects of cannabinoids on MS 
symptoms is represented by the Cannabinoids in Multiple 
Sclerosis (CAMS) study (Zajicek et al 2005). In a randomized, 
placebo-controlled trial, 630 patients with stable MS and muscle Neuropsychiatric Disease and Treatment 2008:4(5) 851
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spasticity were enrolled. 630 participants were treated 
at 33 UK centers with oral cannabis extract (n = 211), 
Δ9-tetrahydrocannabinol (Δ9-THC; n = 206), or placebo 
(n = 213). Trial duration was 15 weeks. The primary outcome 
measure was the Ashworth assessment of muscle spasticity, 
but other MS related symptoms, disability, and safety were 
also evaluated.
There was evidence of a treatment effect on patient-
reported spasticity and pain (p = 0.003), with improvement 
in spasticity reported in 61%, 60%, and 46% of participants 
on cannabis extract, Δ9-THC, and placebo, respectively.
The main study covered 15 weeks, with all patients dis-
continuing treatment during week 14. There was no evidence 
of treatment effects on change in Ashworth score or other 
measures of disability from baseline to week 13. However, 
there was evidence of improvement in walking time for 
ambulatory patients and in patient perceptions of spastic-
ity, muscle spasms, pain, and sleep. There was evidence of 
patient unmasking, complicating interpretation of patient 
assessed outcomes.These ﬁ  ndings are consistent with those 
of smaller studies, (Petro and Ellenberger 1981; Ungerleider 
et al 1987; Greenberg et al 1994; Killestein et al 2002) 
which showed some subjective, but no observer-veriﬁ  ed, 
improvement in disease-related spasticity with use of 
cannabinoids.
The results of the CAMS study are also consistent with 
a report from a crossover study (Vaney et al 2003), the 
ﬁ  ndings of which indicated trends in reduction of spasms 
and improved mobility in 50 patients who received can-
nabis extract. A subsequent study was performed to assess 
the effectiveness and long-term safety of cannabinoids in 
MS, in a follow-up to the main CAMS study. 630 patients 
with stable MS with muscle spasticity from 33 UK centers 
were randomized to receive oral Δ9-tetrahydrocannabinol 
(Δ9-THC), cannabis extract, or placebo in the main 15 week 
CAMS study. The primary outcome was change in the 
Ashworth spasticity scale. Secondary outcomes were the 
Rivermead Mobility Index, timed 10-m walk, UK Neu-
rological Disability Score, postal Barthel Index, General 
Health Questionnaire-30, and a series of 9 category rating 
scales. Following the main study, patients were invited to 
continue medication, double blinded, for up to12 months in 
the follow-up study. Evidence of a small treatment effect 
on muscle spasticity as measured by change in Ashworth 
score from baseline to 12 months was observed. There 
was suggestive evidence for treatment effects of Δ9-THC 
on some aspects of disability. There were no major safety 
concerns. Overall, patients felt that these drugs were helpful 
in treating their disease. These data provide limited evidence 
for a longer term treatment effect of cannabinoids. Another 
clinical study deals with Sativex®, a combined cannabinoid 
medicine constituted by THC and cannabidiol (CBD) in a 
1:1 ratio (Smith 2007), developed by GW Pharmaceuticals. 
Sativex, via an oromucosal pump spray, has proved to 
be well tolerated and successfully self-administered and 
self-titrated in both healthy volunteers and patient cohorts. 
Clinical assessment of this combined cannabinoid medicine 
has demonstrated efﬁ  cacy in patients with intractable pain 
(chronic neuropathic pain, pain due to brachial plexus nerve 
injury, allodynic peripheral neuropathic pain, and advanced 
cancer pain), rheumatoid arthritis and MS (bladder problems, 
spasticity and central pain), with no signiﬁ  cant intoxication-
like symptoms, tolerance or withdrawal syndrome (Perez 
2006). Sativex® was effective, with no evidence of toler-
ance, in select patients with central neuropathic pain and 
MS who completed approximately 2 years of treatment 
(n = 28). Ninety-two percent of patients experienced an 
adverse event, the most common of which were dizziness 
and nausea. Most adverse events were deemed to be of mild 
to moderate severity by the investigators (Rog et al 2007). 
There is still concern about potential side effects associated 
with a prolonged treatment, thus long term studies are needed 
to establish whether cannabinoids may have a role beyond 
symptom amelioration in MS.
Conclusions
The emerging literature on the effects of endocannabinoids 
and new cannabinoid-derived molecules on MS could lead 
to the development of promising models for the therapy 
and management of disabling symptoms of the disease. 
Considering that current treatments of MS are partially 
effective and have risks of side effects not easily tolerated 
by patients, the development of new synthetic endocan-
nabinoids or cannabinoid-derived drugs could represent an 
alternative strategy to pursue. A crucial point that deserves 
further investigation is the full assessment of the possible 
psychotropic side effects that represent the limits to the use 
of cannabimimetic drugs in MS therapy. The possibility of 
overcoming these side effects to develop novel approaches 
represents the main open question on the use of cannabinoids 
as new therapeutic drugs for the treatment of MS.
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